PharmaFocus Today – Page 73 – media

Study finds Parkinson’s disease SLT more effective than one used in NHS

The progressive neurodegenerative condition affects around 153,000 people in the UK Researchers from the Universities of Nottingham and Birmingham have revealed that a new form of speech therapy was more effective than the speech and language therapy (SLT) currently used in the NHS for Parkinson’s disease (PD). Published in the British Medical Journal, the PD-COMM trial has been evaluating the effectiveness and cost-effectiveness of two forms of SLT for people living with the neurological disease who have self-reported problems with voice or speech. Affecting around 153,000 people in the UK, PD is a neurodegenerative condition in which parts of the brain become progressively damaged, causing problems such as shaking and stiffness. Due to changes in the brain in people with PD, movements in the muscles to generate speech become smaller and less forceful than before, leading to speech and communication problems. Carried out across the UK by NHS Speech and ...
- Source: drugdu
- 78
- July 19, 2024
German CDMO outlays $980m on GLP-1 manufacturing expansion

German contract development and manufacturing organisation (CDMO) Corden Pharma announced a €900m ($980m) investment to expand its diabetes drug manufacturing capabilities, as shortages persist around the world. The company declared that the investment would be used over the next three years to expand its peptide manufacturing capabilities at sites in Colorado, US, and Europe. The facilities will have a particular focus on GLP-1 peptide manufacturing, as the demand increases. In a 16 July press release, the company spoke of multiple long-term contracts worth more than €3bn with potential benefits. Last year, the company signed a major deal with Eli Lilly to manufacture the active pharmaceutical ingredient for its leading obesity drug Mounjaro (tirzepatide), as per a Reuters report. In January 2023, the company also shared the signing of a $1bn multi-year agreement to manufacture a large volume peptide with an undisclosed company. The latest investment will be used to construct ...
- Source: drugdu
- 76
- July 19, 2024
Revolution sets sights on Phase III trial for pan-RAS inhibitor

Revolution Medicine plans to kickstart a Phase III trial following positive data from a first-in-human study of its investigational KRAS inhibitor RMC-6236 in pancreatic cancer patients. In an investor deck released yesterday [15 July], the company outlined updated data from the Phase I trial (NCT05379985) that outlined responses from 127 patients with pancreatic ductal carcinoma (PDAC) who received between a dose of RMC-6236 ranging from 160mg to 300mg. Median progression-free survival was 8.1 months in patients with the KRAS G12X mutation, and 7.6 months in those who broadly have RAS-mutant tumours. Among participants who had at least three prior treatment regimens, the median progression-free survival was 4.2 months. Out of the 127 participants, 96% suffered from side effects. The most common were rashes, diarrhoea, nausea, and mouth sores. Those adverse events were deemed severe or medically significant in 28% of patients. The company had previously presented early Phase I data, ...
- Source: drugdu
- 76
- July 19, 2024
Innovative C. Difficile Diagnostic Test Provides Both GDH and Toxin Results within 30 Minutes

Clostridium difficile is a leading cause of hospital-acquired diarrhea and pseudomembranous colitis. Infections typically occur when antibiotics disrupt the normal gut flora. Toxigenic strains of C. difficile produce toxins A and B, which are responsible for the symptoms of the infection. Diagnosing C. difficile can be complex because it is possible to carry the bacteria without it producing disease-causing toxins. All strains of C. difficile produce glutamate dehydrogenase (GDH), making GDH testing a useful initial screen for the infection. However, additional tests are necessary since a GDH-positive result does not confirm if the strain is toxin-producing, which is necessary to determine if the patient has an active infection or is just a carrier. Now, a new test that provides results for both GDH and the toxins within approximately 30 minutes can help healthcare professionals accurately distinguish between active infection and colonization in a cost-effective and clinically relevant way. The C. ...
- Source: drugdu
- 70
- July 18, 2024
AI Identifies Drug-Resistant Typhoid-Like Infection from Microscopy Images within Hours

Antimicrobial resistance is becoming a serious global health concern, making many infections increasingly difficult to treat and limiting available treatment options. This escalation in resistance raises the concern of some infections soon becoming untreatable. A major challenge for healthcare providers is quickly distinguishing between organisms that respond to standard first-line drugs and those that are resistant. Traditional testing methods, which involve culturing bacteria, testing them against various antimicrobial agents, and either manual or machine analysis, can take several days. This delay often leads to the administration of ineffective drugs, which can cause more severe health issues and potentially contribute to the development of further drug resistance. Researchers have now demonstrated that artificial intelligence (AI) can significantly cut down the time needed to accurately diagnose drug-resistant infections. They have developed an algorithm capable of correctly identifying drug-resistant bacteria from microscopy images alone. In research published in Nature Communications, the team of ...
- Source: drugdu
- 76
- July 18, 2024
NIHR and Diabetes UK invest nearly £3m to prevent and treat diabetes distress

The National Institute for Health and Care Research (NIHR) and Diabetes UK have partnered, investing nearly £3m, to develop research to treat and prevent type 1 diabetes (T1D) distress. The new funding, awarded to Professor Jackie Sturt at King’s College London, will help to test a new programme known as ‘D-Stress’ to help tackle the overwhelming burden for adults living with the chronic condition. According to Diabetes UK, around 4.4 million people in the UK are living with diabetes, a metabolic disease characterised by elevated levels of blood glucose. Occurring when the pancreas does not produce insulin or makes very little insulin, T1D accounts for approximately 10% of diabetes cases in the UK and almost 50% of adults living with the condition experience high levels of diabetes distress. The new programme aims to deliver care within the NHS for the detection, prevention and management of T1D in adults and will ...
- Source: drugdu
- 77
- July 18, 2024
Trial finds over-the-counter nasal sprays could reduce RTIs and antibiotic use

A new trial led by researchers from the University of Southampton in partnership with the University of Bristol has revealed that over-the-counter nasal sprays could help to reduce upper respiratory tract infections (RTIs), as well as the use of antibiotics. The study, published in the Lancet Respiratory Medicine and funded by the National Institute for Health and Care Research, found that nasal sprays could prevent severe symptoms of RTIs from developing. Affecting one in five people in England, RTIs are infections of parts of the body involved in breathing, including the sinuses, throat, airways or lungs. Affecting the upper areas of the respiratory system, such as the sinuses and throat, upper respiratory infection symptoms include a runny nose, sore throat and cough. Researchers analysed data from nearly 14,000 adults from 322 GP practices who experienced health problems or risk factors for infections that included either two existing health problems, a ...
- Source: drugdu
- 75
- July 18, 2024
Accounting Standards Committee of the Ministry of Finance Visited Fosun Pharmaceuticals to Conduct Research on Equity Method Project

Recently, Mr. Zhang Juan, Deputy Director of Accounting Standards Committee of the Ministry of Finance, and his team visited Fosun Pharmaceuticals’ Shanghai headquarters to conduct a special investigation on the equity method project, and Mr. Sun Mei, Partner of Ernst & Young’s Technology Department, participated in the investigation together. The research centered on the equity method project being carried out by the International Accounting Standards Board (IASB), and included research and exchanges on the practical application of the equity method on the enterprise side. Mr. Guan Xiaohui, Executive Director and Vice Chairman of Fosun Pharma, welcomed the delegation of the Accounting Standards Committee of the Ministry of Finance and believed that this exchange would help to improve the quality of the company’s accounting information and further understanding of accounting standards. Mr. Guan indicated that Fosun has always attached great importance to the compliance of financial information disclosure, and has continuously ...
- Source: drugdu
- 84
- July 18, 2024
Nature Medicine publishes latest results of combination chemotherapy with Benmelstobart and anlotinib, with a median OS of 19.32 months in SCLC

On July 11, encouraging news came from the ETER701 study completed by 72 centers nationwide led by Professor Cheng Ying of Jilin Cancer Hospital. The academic paper Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial was published online in the international authoritative medical journal Nature ETER701 was a study of Chiatai Tianqing’s Benmelstobart and anlotinib in combination with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. The study showed that the median progression-free survival (mPFS) and median overall survival (mOS) of patients included in the current study were the highest in the history of the registry study, and that the combination chemotherapy regimen of Benmelstobart and amlotinib is expected to provide a survival benefit for patients with extensive-stage small cell lung cancer (ES-SCLC). This is another authoritative recognition of Benmelstobart in combination with amlotinib and chemotherapy in the field of extensive-stage small ...
- Source: drugdu
- 84
- July 18, 2024
SOTIO Biotech, Biocytogen Ink Research and License Agreement to Develop Next-Generation Antibody-Drug Conjugates

By Don Tracy, Associate Editor The agreement enables SOTIO to license multiple fully human bispecific antibodies from Biocytogen’s RenLite platform. SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, and Biocytogen have agreed to terms on a research collaboration and exclusive option and license agreement. According to the companies, the deal will aim to develop next-generation antibody-drug conjugates (ADCs) for targeting solid tumors, while SOTIO will also have the ability to utilize Biocytogen’s proprietary ADC platform. “SOTIO’s powerful ADC platform brings together multiple technologies, allowing us to tailor our therapeutics to meet the needs of specific cancer types. Specifically, exploiting bispecific targeting in the context of our ADC approaches to improve precision targeting and overcome tumor heterogeneity is particularly appealing,” said Martin Steegmaier, PhD, chief scientific officer SOTIO, in a press release. “This agreement with Biocytogen complements our existing collaborations with Synaffix, LigaChem, and NBE-Therapeutics, providing SOTIO with access ...
- Source: drugdu
- 83
- July 18, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.